Third time's not a charm: Depomed rejects Horizon Pharma again
Depomed said Horizon Pharma's latest all-stock bid had a current value of $30 per share, or about $1.81 billion, lower than Horizon's previous offer of $33.
Horizon Pharma said last Thursday it would offer 0.95 Horizon Pharma shares for every Depomed share. It had also said it could alternatively offer Depomed shareholders $32.50 in cash and stock.
Horizon Pharma first approached Depomed in May and went hostile with its offer in July after being rejected. Depomed adopted a poison pill to stave off the bid. ■